Pharmacoresistance: Mechanisms of pharmcoresistance
Heinemann U, Gabriel S, Salar S (2016)
Publication Type: Book chapter / Article in edited volumes
Publication year: 2016
Publisher: Elsevier Science Ltd.
Edited Volumes: The Curated Reference Collection in Neuroscience and Biobehavioral Psychology
Pages Range: 1138-1143
DOI: 10.1016/B978-0-12-809324-5.00194-2
Abstract
In 30% of epilepsy patients, seizure control by antiepileptic drugs (AED) is insufficient. The mechanisms underlying pharmacoresistance vary. The target hypothesis proposes that pharmacoresistance is caused by changes of the properties of drug targets. The transporter hypothesis argues that the expression or function of multidrug transporters in the brain is augmented, leading to impaired access of AEDs to central nervous system (CNS) targets. The leaky blood brain barrier hypothesis suggests that albumin entering the brain interstitial space buffers anticonvulsants or agents needed for their action such as GABA. In addition, the severity hypothesis suggesting that AEDs may not be strong enough in controlling intense seizures, network reorganization, and development of tolerance may contribute in some cases.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Heinemann, U., Gabriel, S., & Salar, S. (2016). Pharmacoresistance: Mechanisms of pharmcoresistance. In The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. (pp. 1138-1143). Elsevier Science Ltd..
MLA:
Heinemann, U., S. Gabriel, and Seda Salar. "Pharmacoresistance: Mechanisms of pharmcoresistance." The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Elsevier Science Ltd., 2016. 1138-1143.
BibTeX: Download